Daratumumab, Bortezomib, Lenalidomide and Dexamethasone, Upfront Autologous Transplant and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma.

Pasvolsky O, Abid MB, Milton DR, Tanner MR, Irfan S, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Haider AA, Aljawai Y, Kebriaei P, Patel KK, Ye C, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH

Open source

DOI: 10.1016/j.jtct.2026.11.011
Published: 2026 Nov 7
Container: Transplantation and cellular therapy
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtct.2026.11.011,
  title = {Daratumumab, Bortezomib, Lenalidomide and Dexamethasone, Upfront Autologous Transplant and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma.},
  author = {Pasvolsky O and Abid MB and Milton DR and Tanner MR and Irfan S and Bashir Q and Srour S and Saini N and Lin P and Ramdial J and Nieto Y and Tang G and Haider AA and Aljawai Y and Kebriaei P and Patel KK and Ye C and Thomas SK and Orlowski RZ and Champlin RE and Shpall EJ and Qazilbash MH},
  year = {2026},
  journal = {Transplantation and cellular therapy},
  doi = {10.1016/j.jtct.2026.11.011},
  url = {https://doi.org/10.1016/j.jtct.2026.11.011}
}

RIS

TY  - JOUR
TI  - Daratumumab, Bortezomib, Lenalidomide and Dexamethasone, Upfront Autologous Transplant and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma.
AU  - Pasvolsky O
AU  - Abid MB
AU  - Milton DR
AU  - Tanner MR
AU  - Irfan S
AU  - Bashir Q
AU  - Srour S
AU  - Saini N
AU  - Lin P
AU  - Ramdial J
AU  - Nieto Y
AU  - Tang G
AU  - Haider AA
AU  - Aljawai Y
AU  - Kebriaei P
AU  - Patel KK
AU  - Ye C
AU  - Thomas SK
AU  - Orlowski RZ
AU  - Champlin RE
AU  - Shpall EJ
AU  - Qazilbash MH
PY  - 2026
JO  - Transplantation and cellular therapy
DO  - 10.1016/j.jtct.2026.11.011
UR  - https://doi.org/10.1016/j.jtct.2026.11.011
ER  -

APA

O, P., MB, A., DR, M., MR, T., S, I., Q, B., S, S., N, S., P, L., J, R., Y, N., G, T., AA, H., Y, A., P, K., KK, P., C, Y., SK, T., RZ, O., RE, C., EJ, S., & MH, Q. (2026). Daratumumab, Bortezomib, Lenalidomide and Dexamethasone, Upfront Autologous Transplant and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma.. Transplantation and cellular therapy. https://doi.org/10.1016/j.jtct.2026.11.011

Source records

pubmed · retrieved 2026-11-10T12:57:36.142Z
europe-pmc · retrieved 2026-11-10T12:57:36.155Z